Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CXCR4 | P61073 | 4/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | GPR4 | P46093 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7710736 | 1.00 | SMN1; SMN2 (0.35) | SMN1; SMN2POLBCXCR4SIGMAR1CHRM5 | |
| SCHEMBL3404082 | 1.00 | SMN1; SMN2 (0.35) | SMN1; SMN2POLBCXCR4SIGMAR1CHRM5 | |
| SCHEMBL7707811 | 0.86 | — | — | |
| SCHEMBL7702256 | 0.86 | — | — | |
| SCHEMBL7702258 | 0.86 | — | — | |
| SCHEMBL375245 | 0.80 | — | — | |
| SCHEMBL7704845 | 0.77 | — | — | |
| SCHEMBL21426001 | 0.77 | — | — | |
| SCHEMBL5943069 | 0.77 | — | — | |
| SCHEMBL456596 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3578562-B1 | L-VALINATE AMIDE BENZOXABOROLE DERIVATIVES FOR THE TREATMENT OF PARASITIC DISEASES | ANACOR PHARMACEUTICALS INC (US) | 2021-06-23 | — | — | EP | disclosed |
| EP-2712863-B1 | Novel inhibitors of bacterial biofilms and related methods | SEQUOIA SCIENCES INC (US) | 2014-10-22 | — | — | EP | disclosed |
| US-20130274256-A1 | NOVEL INHIBITORS OF BACTERIAL BIOFILMS AND RELATED METHODS | SEQUOIA SCIENCES, INC. (US) | 2013-10-17 | — | — | US | disclosed |
| US-6359174-B1 | REACTING ALLYL REACTANT WITH ACID CHLORIDE IN PRESENCE OF LEWIS ACID CATALYST | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2002-03-19 | — | — | US | disclosed |
| EP-0494604-B1 | 1-Piperazinyl-2-butenes and 2-butynes, intermediates thereof, a process for their preparation and their use as medicaments | HOECHST MARION ROUSSEL INC (US) | 1998-10-07 | — | — | EP | disclosed |
| EP-0494604-B1 | 1-Piperazinyl-2-butenes and 2-butynes, intermediates thereof, a process for their preparation and their use as medicaments | HOECHST MARION ROUSSEL INC (US) | 1998-10-07 | — | — | EP | disclosed |
| EP-0511610-B1 | Benzisothiazole- and benzisoxazole-3-carboxamides, a process for their preparation and their use as antipsychotic medicaments | HOECHST ROUSSEL PHARMA (US) | 1996-09-11 | — | — | EP | disclosed |
| US-5440048-A | Treating psychoses | HOECHST-ROUSSEL PHARMACEUTICALS INC (US) | 1995-08-08 | — | — | US | disclosed |
| US-5440048-A | Treating psychoses | HOECHST-ROUSSEL PHARMACEUTICALS INC (US) | 1995-08-08 | — | — | US | disclosed |
| US-5440048-A | Treating psychoses | HOECHST-ROUSSEL PHARMACEUTICALS INC (US) | 1995-08-08 | — | — | US | disclosed |
| US-5194436-A | For trating psychosis | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1993-03-16 | — | — | US | disclosed |
| EP-0511610-A1 | Benzisothiazole- and benzisoxazole-3-carboxamides, a process for their preparation and their use as antipsychotic medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1992-11-04 | — | — | EP | disclosed |
| US-5143923-A | Psychological disorders | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1992-09-01 | — | — | US | disclosed |
| EP-0494604-A1 | 1-Piperazinyl-2-butenes and 2-butynes, intermediates thereof, a process for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1992-07-15 | — | — | EP | disclosed |
| EP-0494604-A1 | 1-Piperazinyl-2-butenes and 2-butynes, intermediates thereof, a process for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1992-07-15 | — | — | EP | disclosed |
| EP-0494604-A1 | 1-Piperazinyl-2-butenes and 2-butynes, intermediates thereof, a process for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1992-07-15 | — | — | EP | disclosed |
| US-5130315-A | Treatment of psychosis | Wittekind, Raymond R. (US) | 1992-07-14 | — | — | US | disclosed |
| US-5130315-A | Treatment of psychosis | Wittekind, Raymond R. (US) | 1992-07-14 | — | — | US | disclosed |
| US-4213984-A | ANTIULCER AGENTS, ANTISECRETORY AGENTS | BOEHRINGER INGELHEIM GMBH (DE) | 1980-07-22 | — | — | US | disclosed |
| US-4016274-A | TRANQUILIZERS AND ANTICONVULSANT AGENTS | RHONE-POULENC S.A. (FR) | 1977-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274256-A1 | NOVEL INHIBITORS OF BACTERIAL BIOFILMS AND RELATED METHODS | BLVRB, MMP8, PGLS | SMN1; SMN2 4885/4885POLB 725/4885CXCR4 3661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.